UPDATE: JPMorgan Downgrades ObsEva (OBSV) to Underweight on Continued Cash Woes into PRIMROSE Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
November 9, 2020 1:00 AM ESTÂ
Geneva, Switzerland and Boston, MA November 9, 2020 ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health today announced that ObsEvas Board of Directors has appointed Brian OCallaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the companys Executive Committee, effective 1 December 2020. He will also be proposed for election on ObsEvas Board of Directors at next company AGM.
As ObsEva evolves from a development company towards commercialization, Dr Ernest Loumaye,... More
ObsEva Announces Third Quarter 2020 Financial Results and Business Update
November 5, 2020 1:00 AM ESTPositive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual CongressLinzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.Actively discussing commercial partnership to maximize linzagolix best-in-class... More
ObsEva Announces Third Quarter 2020 Financial Results and Business Update
November 5, 2020 1:00 AM ESTPositive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual CongressLinzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.Actively discussing commercial partnership to maximize linzagolix best-in-class... More
